What is Destiny Pharma?
Destiny Pharma is dedicated to combating the growing threat of antimicrobial resistance through its unique XF drug platform. The company's lead asset, XF-73, is undergoing clinical development for the prevention of serious post-surgical infections, having demonstrated promising clinical trial data. Beyond surgical site infections, Destiny Pharma is also advancing a dermal formulation of XF-73 for the treatment of bacterial skin infections, a project bolstered by support from the US National Institute for Allergy and Infectious Diseases. The company's approach targets an ultra-rapid mechanism to neutralize bacteria, positioning it at the forefront of infection prevention strategies.
How much funding has Destiny Pharma raised?
Destiny Pharma has raised a total of $24.5M across 2 funding rounds:
Unspecified
$4.7M
Stock Offering
$19.8M
Unspecified (2014): $4.7M with participation from Angel CoFund
Stock Issuance/Offering (2017): $19.8M, investors not publicly disclosed
Key Investors in Destiny Pharma
Angel CoFund
Angel CoFund is a UK-based investment fund that supports promising businesses through angel and co-investment, collaborating with sector-focused angel investors to enhance the investment process and drive capital growth.
What's next for Destiny Pharma?
The substantial enterprise-level funding and recent strategic investment indicate Destiny Pharma is poised for significant scaling and advancement of its clinical pipeline. This capital infusion is expected to accelerate the development of XF-73 through further clinical trials and regulatory submissions, potentially bringing its innovative anti-infective solutions to market. The company's focus on addressing critical unmet needs in infection prevention, especially in hospital environments, suggests a strategic expansion of its commercialization efforts and potential partnerships to broaden its global reach. Destiny Pharma's trajectory points towards becoming a key player in the fight against antibiotic-resistant bacteria.
See full Destiny Pharma company page
